Jinghua Pharmaceutical Group Co Ltd

Jinghua Pharmaceutical Group Co Ltd maintains a strong liquidity position, with a current ratio of 5.13, indicating that it has more than five times the current assets to cover its current liabilities. The company's liquidity FPT (free cash flow to total debt) is robust, supported by a free cash flow of 247.65 million CNY and a low long-term debt of 27.26 million CNY, resulting in a debt-to-equity ratio of 0.01. The company's valuation metrics, including a price-to-book ratio of 2.09 and a price-to-earnings ratio of 26.22, suggest that it is moderately valued relative to its book value and earnings.

In terms of profitability, Jinghua Pharmaceutical Group Co Ltd demonstrates a return on equity (ROE) of 7.97% and a return on assets (ROA) of 6.14%, which are in line with the industry's preferred metrics for pharmaceutical companies. The company's gross profit of 746.80 million CNY and operating income of 303.14 million CNY indicate a healthy margin structure, although the net income of 219.28 million CNY suggests some pressure from operating expenses.

The company's revenue is primarily concentrated in its domestic market, with no significant international exposure disclosed in the financial data. This concentration may pose a risk if the domestic market experiences regulatory or economic shifts. The company's revenue of 1.46 billion CNY is derived from a single business segment, which is typical for a focused pharmaceutical company.

Looking ahead, Jinghua Pharmaceutical Group Co Ltd is expected to maintain a stable growth trajectory, with no significant changes in revenue or earnings projected for the next fiscal year. The company's capital expenditure of -20.32 million CNY indicates a reduction in investment, which may be a strategic move to preserve cash or a sign of reduced expansion plans. The company's risk assessment indicates a medium liquidity risk and a low dilution risk, with no immediate pressure for equity issuance.

Recent events and filings do not indicate any material changes in the company's operations or financial position. The company's financial statements and disclosures have not revealed any significant legal, regulatory, or operational risks that would impact its near-term performance. The company's operating cash flow of 340.87 million CNY supports its liquidity and provides a buffer against potential short-term financial stress.

Jinghua Pharmaceutical Group Co Ltd (002349.SZ) has undergone a formal classification update, with its economic sector now explicitly identified as Healthcare and its primary activity defined as Pharmaceuticals. This structural clarification serves as the most material change in the company's recent profile, establishing a clear baseline for its operational identity within the broader market taxonomy. Alongside this sectoral definition, the company’s risk assessment framework has been initialized with specific metrics. Dilution risk is currently rated as low, indicating a stable capital structure with minimal immediate threat of share value erosion from new issuances. This assessment provides a foundational view of shareholder equity protection. Conversely, liquidity risk has been classified as medium, suggesting that while the company maintains operational viability, there may be moderate constraints or variability in its short-term cash flow management or market trading depth. This distinction highlights a key area for ongoing monitoring, balancing the low dilution risk against potential liquidity considerations. These updates collectively refine the analytical profile of Jinghua Pharmaceutical, moving from an undefined state to a structured assessment of its sectoral role and financial risks. The establishment of these baseline metrics—low dilution, medium liquidity, and clear pharmaceutical sector alignment—provides investors with a more precise framework for evaluating the company’s stability and operational context. [doc:002349.sz-ha-financials]